Oxidative Stress and Its Molecular Effectors in Uterine Smooth Muscle Tumors: Bridging Epigenetic Regulation and Glycoprotein Biomarkers
Open Access
- 30 September 2026
- journal article
- review article
- Published by MDPI AG in Antioxidants
- Vol. 15 (10) , 1252
Abstract
Background: Uterine smooth muscle tumors present a diverse clinical spectrum, ranging from ubiquitous benign leiomyomas to highly lethal uterine leiomyosarcomas (uLMSs). The preoperative differentiation of these entities, alongside the intermediate smooth muscle tumors of uncertain malignant potential (STUMP), remains an unresolved clinical challenge. Methods: This comprehensive review synthesizes the current literature on the pathogenesis of uterine smooth muscle tumors, focusing on the role of oxidative stress and its downstream molecular effectors. We evaluate the interplay between oxidative stress markers, epigenetic regulation via microRNAs (miRNAs), and circulating glycoproteins. Results: Increased oxidative stress is a hallmark associated with uLMS, characterized by altered antioxidant enzyme activity and elevated lipid peroxidation products such as malondialdehyde (MDA). This oxidative burden is associated with DNA damage and profound genomic instability, participating in the evolution of the malignant phenotype. Concurrently, the stressed tumor microenvironment exhibits significant epigenetic deregulation. Tumor-suppressive miRNAs (e.g., the miR-29 and miR-200 families) are downregulated, while oncogenic miRNAs (e.g., miR-21) are upregulated, promoting survival and proliferation pathways. Furthermore, galectin-1, a glycoprotein responsive to microenvironmental stress, is elevated in the serum of uLMS and STUMP patients, demonstrating high specificity in investigated cohorts, though limited sensitivity (47%), whereas mucin-1 (MUC1) shows no significant diagnostic utility. Conclusions: Oxidative stress is strongly associated with the genomic instability and molecular derangements observed in uterine sarcomas. Integrating oxidative stress indicators with specific miRNA signatures and galectin-1 levels could potentially yield robust, non-invasive diagnostic panels. However, prospective validation in large, independent cohorts is strictly required before these markers can be implemented to improve preoperative risk stratification and guide targeted therapeutic interventions.Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- Proteasome inhibition by bortezomib induces stress-response–mediated cytotoxicity in uterine leiomyosarcoma cellsBiochemical and Biophysical Research Communications, 2026
- MUC1 as a diagnostic biomarker and siRNA-based therapeutic target in breast cancer: A clinical chemistry perspectiveClinica Chimica Acta, 2025
- PI3K/mTOR inhibition induces tumour microenvironment remodelling and sensitises pS6high uterine leiomyosarcoma to PD‐1 blockadeClinical and Translational Medicine, 2024
- Uterine sarcomas: A critical review of the literatureEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2023
- Pre-clinical and clinical importance of miR-21 in human cancers: Tumorigenesis, therapy response, delivery approaches and targeting agentsPharmacological Research, 2022
- A more accurate method to interpret lactate dehydrogenase (LDH) isoenzymes’ results in patients with uterine massesEuropean Journal of Obstetrics & Gynecology and Reproductive Biology, 2019
- Uterine leiomyosarcoma: A review of the literature and update on management optionsGynecologic Oncology, 2018
- Incidence and groups at risk for unexpected uterine leiomyosarcoma: a Dutch nationwide cohort studyArchives of Gynecology and Obstetrics, 2018
- The two FIGO systems for normal and abnormal uterine bleeding symptoms and classification of causes of abnormal uterine bleeding in the reproductive years: 2018 revisionsInternational Journal of Gynecology & Obstetrics, 2018
- MicroRNA therapeutics: towards a new era for the management of cancer and other diseasesNature Reviews Drug Discovery, 2017